Innate Pharma S.A. (EPA: IPH)

Market Cap	169.19M
Revenue (ttm)	61.64M
Net Income (ttm)	-7.57M
Shares Out	80.95M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,269
Open	2.100
Previous Close	2.110
Day's Range	2.090 - 2.125
52-Week Range	1.862 - 3.040
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 12, 2024

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 179
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPH

Financial Performance

In 2023, ALFPC's revenue was 278.34 million, an increase of 25.72% compared to the previous year's 221.40 million. Earnings were 11.43 million, a decrease of -28.16%.